Kinetics of DNA load predict HPV 16 viral clearance

Journal of Clinical Virology

Volumn 51, Issue 1, 2011, Pages 44-49

  Marks, M ^a   Gravitt, P E ^a   Utaipat, U ^a   Gupta, S B ^b   Liaw, K ^b   Kim, E ^a   Tadesse, A ^b   Phongnarisorn, C ^c   Wootipoom, V ^d   Yuenyao, P ^e   Vipupinyo, C ^f   Rugpao, S ^g   Sriplienchan, S ^g   Celentano, D D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f RAJAVITHI HOSPITAL   (Thailand)

^g Research Institute for Health Sciences   (Thailand)

Author keywords

DNA; Epidemiology; HPV; Thailand; Viral load

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOLOGY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION RISK; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THAILAND; VIRAL CLEARANCE; VIRUS LOAD;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; KINETICS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; THAILAND; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 79953751602     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.01.011     Document Type: Article

References (42)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(September (1)):12-19.
2. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24S3(August):S1-S10.
3. Castle P.E., Wacholder S., Sherman M.E., Lorincz A.T., Glass A.G., Scott D.R., et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002, 95(November (10)):2145-2151.
4. Dalstein V., Riethmuller D., Pretet J.L., Le Bail Carval K., Sautiere J.L., Carbillet J.P., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003, 106(September (3)):396-403.
5. Healey S.M., Aronson K.J., Mao Y., Schlecht N.F., Mery L.S., Ferenczy A., et al. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. Sex Transm Dis 2001, 28(December (12)):694-700.
6. Hernandez-Hernandez D.M., Ornelas-Bernal L., Guido-Jimenez M., Apresa-Garcia T., Alvarado-Cabrero I., Salcedo-Vargas M., et al. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol 2003, 90(August (2)):310-317.
7. Hesselink A.T., van den Brule A.J., Brink A.A., Berkhof J., van Kemenade F.J., Verheijen R.H., et al. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer 2004, 102(February (1)):11-18.
8. Ho G.Y., Palan P.R., Basu J., Romney S.L., Kadish A.S., Mikhail M., et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer 1998, 78(November (5)):594-599.
9. Ikenberg H., Goppinger A., Bauer H., Schmitt B. Semiquantitative analysis of human papillomavirus DNA in cervical intraepithelial neoplasia by a differential polymerase chain reaction. J Obstet Gynaecol 1997, 17(March (2)):176-179.
10. Lillo F.B., Lodini S., Ferrari D., Stayton C., Taccagni G., Galli L., et al. Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. Clin Infect Dis 2005, 40(February (3)):451-457.
11. Santos A.L., Derchain S.F., Martins M.R., Sarian L.O., Martinez E.Z., Syrjanen K.J. Human papillomavirus viral load in predicting high-grade CIN in women with cervical smears showing only atypical squamous cells or low-grade squamous intraepithelial lesion. Sao Paulo Med J 2003, 121(November (6)):238-243.
12. Sun C.A., Lai H.C., Chang C.C., Neih S., Yu C.P., Chu T.Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001, 83(October (1)):95-99.
13. Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., Chu T.Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002, 76(January (1)):41-47.
14. Tsai H.T., Wu C.H., Lai H.L., Li R.N., Tung Y.C., Chuang H.Y., et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev 2005, 14(November (11 Pt 1)):2544-2549.
15. Carcopino X., Henry M., Benmoura D., Fallabregues A.S., Richet H., Boubli L., et al. Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol 2006, 78(August (8)):1131-1140.
16. Cricca M., Morselli-Labate A.M., Venturoli S., Ambretti S., Gentilomi G.A., Gallinella G., et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 2007, 106(September (3)):549-557.
17. Fiander A.N., Hart K.W., Hibbitts S.J., Rieck G.C., Tristram A.J., Beukenholdt R.W., et al. Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J Med Virol 2007, 79(September (9)):1366-1369.
18. Forslund O., Lindqvist P., Haadem K., Czegledy J., Hansson B.G. HPV 16 DNA and mRNA in cervical brush samples quantified by PCR and microwell hybridization. J Virol Methods 1997, 69(December (1-2)):209-222.
19. Gravitt P.E., Burk R.D., Lorincz A., Herrero R., Hildesheim A., Sherman M.E., et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003, 12(June (6)):477-484.
20. Ho C.M., Chien T.Y., Huang S.H., Lee B.H., Chang S.F. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006, 102(July (1)):54-60.
21. Lai H.C., Peng M.Y., Nieh S., Yu C.P., Chang C.C., Lin Y.W., et al. Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis. Int J Gynecol Cancer 2006, 16(March-April (2)):730-735.
22. Lo K.W., Yeung S.W., Cheung T.H., Siu N.S., Kahn T., Wong Y.F. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: a study in Chinese population. J Clin Virol 2005, 34(September (1)):76-80.
23. Oikonomou P., Mademtzis I., Messinis I., Tsezou A. Quantitative determination of human telomerase reverse transcriptase messenger RNA expression in premalignant cervical lesions and correlation with human papillomavirus load. Hum Pathol 2006, 37(February (2)):135-142.
24. Rajeevan M.S., Swan D.C., Nisenbaum R., Lee D.R., Vernon S.D., Ruffin M.T., et al. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 2005, 115(May (1)):114-120.
25. Snijders P.J., Hogewoning C.J., Hesselink A.T., Berkhof J., Voorhorst F.J., Bleeker M.C., et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006, 119(September (5)):1102-1107.
26. Swan D.C., Tucker R.A., Tortolero-Luna G., Mitchell M.F., Wideroff L., Unger E.R., et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999, 37(April (4)):1030-1034.
27. Wang-Johanning F., Lu D.W., Wang Y., Johnson M.R., Johanning G.L. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002, 94(April (8)):2199-2210.
28. van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A., et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002, 98(April (4)):590-595.
29. Josefsson A.M., Magnusson P.K., Ylitalo N., Sorensen P., Qwarforth-Tubbin P., Andersen P.K., et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000, 355(June (9222)):2189-2193.
30. Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Ponten J., et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000, 355(June (9222)):2194-2198.
31. Moberg M., Gustavsson I., Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004, 112(December (5)):854-859.
32. Moberg M., Gustavsson I., Wilander E., Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005, 92(March (5)):891-894.
33. Munoz N., Hernandez-Suarez G., Mendez F., Molano M., Posso H., Moreno V., et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009, 100(April (7)):1184-1190.
34. Monnier-Benoit S., Dalstein V., Riethmuller D., Lalaoui N., Mougin C., Pretet J.L. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006, 35(March (3)):270-277.
35. Morrison C.S., Richardson B.A., Mmiro F., Chipato T., Celentano D.D., Luoto J., et al. Hormonal contraception and the risk of HIV acquisition. Aids 2007, 21(January (1)):85-95.
36. Else E.A., Swoyer R., Zhang Y., Taddeo F.J., Bryan J.T., Lawson J., et al. Comparison of real time multiplex HPV PCR assays with Inno-Lipa HPV genotyping extra assay. J Clin Microbiol 2010, November.
37. Iftner T., Germ L., Swoyer R., Kjaer S.K., Breugelmans J.G., Munk C., et al. Study comparing human papillomavirus (HPV) real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J Clin Microbiol 2009, 47(July (7)):2106-2113.
38. Gravitt P.E., Peyton C., Wheeler C., Apple R., Higuchi R., Shah K.V. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 2003, 112(September (1-2)):23-33.
39. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 1(March (24 Suppl.)):S16-S22.
40. Scott M., Stites D.P., Moscicki A.B. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999, 6(September (5)):751-755.
41. de Jong A., van der Burg S.H., Kwappenberg K.M., van der Hulst J.M., Franken K.L., Geluk A., et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002, 62(January (2)):472-479.
42. Welters M.J., de Jong A., van den Eeden S.J., van der Hulst J.M., Kwappenberg K.M., Hassane S., et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003, 63(February (3)):636-641.